RxDoctor Payments Data

Robyn Johnson, MD

Internal Medicine · Albany, GANPI 1013019363

Payments from drug & device makers

$2,016in general payments, 2019–2025

Across 114 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$525
  • Novo Nordisk$312
  • Astellas Pharma US Inc$227
  • Viiv Healthcare Company$137
  • AstraZeneca$98
  • Amgen$90
  • plus $628 from 16 others

What the payments were for

  • Food & beverage$1,91695%
  • Education$1005%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,016 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$78
Medicare patients
14
Services billed
14

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide618$603,480
JanuviaSitagliptin Phosphate188$208,825
EliquisApixaban122$142,094
JardianceEmpagliflozin75$87,889
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$52,394
XareltoRivaroxaban40$41,988
MounjaroTirzepatide33$39,875
EntrestoSacubitril/Valsartan30$35,807
TrulicityDulaglutide35$34,894
FarxigaDapagliflozin Propanediol35$34,160
CreonLipase/Protease/Amylase13$31,534
Lantus SolostarInsulin Glargine,hum.Rec.Anlog153$25,840
MyrbetriqMirabegron34$23,579
SymbicortBudesonide/Formoterol Fumarate68$20,694
Breo ElliptaFluticasone/Vilanterol34$19,483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog Mix 70-30$312$607,570638 claims
MerckJanuvia$50$208,825188 claims
PfizerEliquis, Abrysvo$83$155,759165 claims
Boehringer IngelheimJardiance, Combivent Respimat$16$103,16197 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$525$80,777134 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere, Brilinta$98$79,449137 claims
Lilly USA, LLCMounjaro, Trulicity$61$74,76968 claims
AbbVieCreon, Linzess$47$50,57340 claims
NovartisEntresto$38$35,80730 claims
Astellas Pharma US IncMyrbetriq$227$23,57934 claims
Sanofi-aventis U.S. LLCLantus$41$11,78671 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Albany

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →